EMEA-001220-PIP03-16-M02
Key facts
| Invented name |
Olumiant
|
| Active substance |
Baricitinib
|
| Therapeutic area |
Dermatology
|
| Decision number |
P/0311/2021
|
| PIP number |
EMEA-001220-PIP03-16-M02
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of atopic dermatitis
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Eli Lilly & Company Limited
E-mail: eu_paediatric@lilly.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|
| Compliance procedure number |
EMEA-C-001220-PIP03-16-M02
|
| Compliance opinion date |
11/11/2022
|
| Compliance outcome |
positive
|